Literature DB >> 6524509

Successful use of naltrexone in addicted physicians and business executives.

A M Washton, M S Gold, A C Pottash.   

Abstract

Naltrexone was administered to 114 opiate-dependent business executives and 15 opiate-dependent physicians as part of a comprehensive outpatient aftercare program following inpatient detoxification using clonidine. Over 80% of patients successfully completed at least 6 months of treatment without relapse or re-addiction and were still drug-free at 12-18 month follow-up. Patients who completed at least 6 months of treatment were more likely to be opiate free at follow-up than patients who had dropped out at an earlier point in the program. This study demonstrates that naltrexone can be an extremely useful and appropriate treatment for highly motivated middle/upper class addicts when administered within the context of an intensive high-expectation program.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6524509     DOI: 10.1300/J251v04n02_08

Source DB:  PubMed          Journal:  Adv Alcohol Subst Abuse        ISSN: 0270-3106


  5 in total

1.  Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

Authors:  Maria A Sullivan; Suzanne K Vosburg; Sandra D Comer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-14       Impact factor: 4.530

2.  Assessment of drug abuser treatment needs in Rhode Island.

Authors:  W E McAuliffe; P Breer; N W Ahmadifar; C Spino
Journal:  Am J Public Health       Date:  1991-03       Impact factor: 9.308

Review 3.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

4.  Pharmacological enhancement of naltrexone treatment for opioid dependence: a review.

Authors:  Paolo Mannelli; Kathleen S Peindl; Li-Tzy Wu
Journal:  Subst Abuse Rehabil       Date:  2011-06

Review 5.  Selective review and commentary on emerging pharmacotherapies for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Min Zhao; Suzanne Nielsen; Matthew Torrington; Karen Miotto
Journal:  Subst Abuse Rehabil       Date:  2011-10-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.